K. Soma

发表

2.5 Rheumatoid arthritis – non biologic treatment

H. Valdez, H. Nakamura, S. Zwillich, 2012 .

Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis

L. Takiya, J. Tesser, J. Wollenhaupt, 2020, Clinical Rheumatology.

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

R. Moots, P. Emery, D. Mevorach, 2017, The Lancet.

Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy

J. Smolen, T. Takeuchi, R. Fleischmann, 2021, Arthritis Research & Therapy.

The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial

Elie Needle, P. Biswas, C. Nduaka, 2017, Arthritis & rheumatology.

The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis

E. Lee, J. Gómez-Reino, C. Bingham, 2015, Annals of the rheumatic diseases.

Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study

L. Takiya, Sang-Heon Lee, L. Calabrese, 2020, Arthritis care & research.

Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib

Elie Needle, P. Biswas, H. Valdez, 2020, Annals of the Rheumatic Diseases.

Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group

P. Mease, L. Takiya, R. Fleischmann, 2016, Clinical Rheumatology.

Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies

E. Lee, C. Nduaka, J. Curtis, 2014, The Journal of Rheumatology.

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

Stanley B. Cohen, J. Curtis, J. Wollenhaupt, 2019, Arthritis Research & Therapy.

Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme

E. Lee, J. Curtis, J. Geier, 2015, Annals of the rheumatic diseases.

Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis

I. McInnes, P. Biswas, H. Valdez, 2019, Arthritis & rheumatology.

Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques

B. Wyman, D. M. van der Heijde, T. Fuerst, 2016, Annals of the rheumatic diseases.

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

Tamas Koncz, David Gruben, Ricardo Blanco, 2013, The Lancet.

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis

G. Firestein, P. Mease, D. Boyle, 2013, Annals of the rheumatic diseases.

Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor.

M. González-Gay, J. Geier, A. Zuckerman, 2016, Seminars in arthritis and rheumatism.

Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial

R. Moots, V. Strand, J. Smolen, 2019, RMD Open.

Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs

C. Zerbini, G. Burmester, T. Hendrikx, 2015, Annals of the rheumatic diseases.

Ef fi cacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs

C. Zerbini, G. Burmester, T. Hendrikx, 2015 .

Analysis of Infections and All‐Cause Mortality in Phase II, Phase III, and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis

H. Valdez, J. Gómez-Reino, S. Radominski, 2014, Arthritis & rheumatology.

Demographic diversity of participants in Pfizer sponsored clinical trials in the United States.

B. Corrigan, P. Thadeio, A. Schettino, 2021, Contemporary clinical trials.

Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population

P. Nash, S. Hall, K. Thirunavukkarasu, 2018, Rheumatology and Therapy.

EVALUATION OF THE SENSITIVITY OF URETHRAL PRESSURE REFLECTOMETRY (UPR) AND URETHRAL PRESSURE PROFILOMETRY (UPP) TO DETECT PHARMACOLOGICAL AUGMENTATION OF URETHRAL PRESSURE, USING [S,S]-REBOXETINE

G. Lose, K. Soma, A. Darekar, 2008 .

A PHASE 2, 8-WEEK, MULTI-CENTER, RANDOMIZED DOUBLE- BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY EVALUATING THE EFFICACY, TOLERABILITY AND SAFETY OF [S,S] - REBOXETINE (PNU-165442G) FOR STRESS URINARY INCONTINENCE IN WOMEN

N. Zinner, K. Soma, A. Darekar, 2008 .

Measurement of urethral closure function in women with stress urinary incontinence.

G. Lose, K. Soma, A. Darekar, 2009, The Journal of urology.

OP0163 Evaluation of Influenza and Pneumococcal Vaccine Responses in Rheumatoid Arthritis Patients Using Tofacitinib

C. Mebus, T. Kawabata, S. Zwillich, 2013 .

Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs

K. Thirunavukkarasu, W. Bensen, J. Kaine, 2018, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

THU0147 Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancies across the Rheumatoid Arthritis Clinical Programme

X. Mariette, J. Geier, R. Riese, 2014 .

SAT0222 Effects of Tofacitinib on MRI Endpoints in Methotrexate-Naive Early Rheumatoid Arthritis: A Phase 2 MRI Study with Semi-Quantitative and Quantitative Endpoints

B. Wyman, D. M. van der Heijde, T. Fuerst, 2015 .

Analysis of Infections and All‐Cause Mortality in Phase II, Phase III, and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis

H. Valdez, J. Gómez-Reino, S. Radominski, 2014, Arthritis & rheumatology.